SCHERING-PLOUGH RESEARCH INSTITUTE

ACTIVE

15915 Hampton Village Dr, Tampa, New Jersey, United StatesSubsidiary

Part of Schering-Plough Corp.

Clinical Trials

206

142 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

37.4%

Not Applicable

29.1%

Trial Status Distribution

Active, not recruiting

142

68.9%

Completed

29.6%

Clinical Trials

Trials sponsored by this organization (206)

A PHASE 3, 40-WEEK, ACTIVE-CONTROLLED, DOUBLE-BLIND EXTENSION STUDY OF PRELADENANT IN SUBJECTS WITH MODERATE TO SEVERE PARKINSON´S DISEASE (PHASE 3, PROTOCOL N° P06153)

Not Applicable

interventional

Jun 2011

PHARMACOKINETICS AND SAFETY OF ORAL POSACONAZOLE (SCH56592) IN SUBJECTS AT HIGH RISK FOR INVASIVE FUNGAL DISEASE. (PROTOCOL Nº P05615 PHASE1B)

Not Applicable

Completed

interventional

Feb 20115 participants

A Study to Determine the Activity of SCH 717454 in Subjects With Osteosarcoma or Ewing’s Sarcoma That Has Relapsed After Standard Systemic Therapy. - P04720

Active, not recruiting

Dec 2010222 participants

A PHASE 3, DOUBLE-BLIND, PLACEBO-AND ACTIVE-CONTROLLED DOSE RANGE-FINDING EFFICACY AND SAFETY STUDY OF PRELADENANT IN SUBJECTS WITH EARLY PARKINSON´S DISEASE (PHASE 3 PROTOCOL N°. P05664)

A PHASE 3, 12-WEEK, DOUBLE-BLIND, PLACEBO-AND ACTIVE-CONTROLLED EFFICACY AND SAFETY STUDY OF PRELADENANT IN SUBJECTS WITH MODERATE TO SEVERE PARKINSON´S DISEASE. (PHASE3; PROTOCOL N°. P04938)

Not Applicable

Completed

interventional

Nov 201055 participants

Proof-of-Concept and Dose Range-Finding Study of SCH 527123 in Subjects with Severe Asthma

Active, not recruiting

Oct 2010500 participants

A 2-Year, Dose Range-Finding, Adaptive-Design Study of the Effects of SCH 527123 inSubjects With Moderate to Severe COPD

Active, not recruiting

Oct 2010500 participants

AN 8-WEEK, PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED, FIXED-DOSE EFFICACY AND SAFETY TRIAL OF ASENAPINE IN ADOLESCENT SUBJECTS WITH SCHIZOPHRENIA

Page 1 of 26

Approvals

No approval data available

News

No news articles found

Back to Organizations